Combat-associated traumatic hemorrhage remains a primary cause of preventable mortality in the military. As evidenced by robust clinical studies and dictated by current Remote Damage Control Resuscitation (RDCR) principles, timely transfusion of blood components (platelets, RBC, plasma) to mitigate hemorrhagic shock strongly improves combat casualty survival. However, blood components, especially platelets, have very limited availability far forward and there is a severe lack of field-deployable platelet products to enable effective in-field Hemostatic Resuscitation (HR). Lyophilized, low-volume, portable, easily storable, saline-reconstitutable synthetic platelet surrogate technology can potentially address this significant challenge and improve survival outcomes. To this end, we have developed a liposome-templated synthetic platelet surrogate technology (SynthoPlate (SP), US 9107845 and US 93636383, TRL 4) that has demonstrated systemic safety, targeted hemostatic efficacy and survival improvement in pilot studies in mouse, rat and pig hemorrhagic trauma models. We have established the ability to lyophilize and reconstitute SynthoPlate particles, as well as the ability to sterilize them for long term storage (12 months), without compromising their stability and platelet-mimetic bioactivity. Building on these successful capabilities, we propose the translational development of the lyophilized SynthoPlate (Lyo-SP) nanotechnology as an intravenous or intraosseous administrable platelet surrogate product with a vision for RDCR application in combat-associated trauma for point-of-injury hemorrhage control and TIC management.